HER2-Positive gastric cancer: Consequences for targeted therapy

Abstract

Author(s): Salahuddin, Kavina Ganapathy, Krishan Kumar

Objective: The anti-drug combination known as trastuzumab deruxtecan is composed of a cytotoxicity topoisomerase I inhibitor, a cleavable tetrapeptidebased linker, and an anti-HER2 (Human Epidermal Growth Factors Receptor 2) antibody. This combination is designed to combat cancer. Patients diagnosed with advanced HER2-Positive Gastric Cancer (PSC) may benefit from the use of this medication.

Materials and Methods: Participants in our phase 2 trial with cancerous HER2-positive gastric cancer were allocated at random to receive the treatment trastuzumab-deruxtecan or chemotherapy, and we compared the two treatments. Trastuzumab deruxtecan (T-DXd) or the doctor's choice of chemotherapy was randomly distributed to patients with centralized proven HER2-positive gastric cancer the connection had received at least two previous treatments for their developed adenocarcinoma, such as trastuzumab. According to the impartial central review's results, the objective response was the main goal. Secondary end objectives were response duration, progression-free survival, verified response, and safety in addition to general survival.

Results: Out of 187 patients who got treatment, 125 obtained T-DXd and 62 chemotherapy treatments. In the T-DXd group, 49% of patients reported a realistic response in contrast to 18% of patients in the Doctors' selection association. T-DXd improved overall survival compared to chemotherapy. An independent committee determined that a total of 12 individuals experienced interstitial lung illness or pneumonitis caused by T-DXd. In the T-DXd group, there was one drug-related fatality; there were none in the Doctors' Preference Group.

Conclusion: When compared to those who received standard therapy, persons who had chemotherapy for HER2-positive gastric cancer treated with T-DXd demonstrated significantly better responses and overall survival. Interstitial lung disease and a weakened immune system were the most noticeable negative effects.

Share this article

Awards Nomination

Editors List

  • Ahmed Hussien Alshewered

    University of Basrah College of Medicine, Iraq

  • Sudhakar Tummala

    Department of Electronics and Communication Engineering SRM University – AP, Andhra Pradesh

     

     

     

  • Alphonse Laya

    Supervisor of Biochemistry Lab and PhD. students of Faculty of Science, Department of Chemistry and Department of Chemis

     

  • Fava Maria Giovanna

     

  • Manuprasad Avaronnan

Google Scholar citation report
Citations : 558

Onkologia i Radioterapia received 558 citations as per Google Scholar report

Onkologia i Radioterapia peer review process verified at publons
Indexed In
  • Directory of Open Access Journals
  • Scimago
  • SCOPUS
  • EBSCO A-Z
  • MIAR
  • Euro Pub
  • Google Scholar
  • Medical Project Poland
  • PUBMED
  • Cancer Index
  • Gdansk University of Technology, Ministry Points 20